{"title":"Further analyses from DEPICT: Dapagliflozin in Type 1 Diabetes (https://doi.org/10.1111/dom.13972)","authors":"","doi":"10.1002/doi2.00009","DOIUrl":null,"url":null,"abstract":"<p>A research group from Cardiff, UK, has analysed data from the DEPICT clinical trial program and used a novel modelling approach to investigate the inter-relationships between hypoglycaemia, BMI and quality of life (QoL). Episodes of severe hypoglycaemia were associated with a significant increase in the ‘hypoglycemia fear score’ (HFS), and there was evidence that increased HFS and/or increased BMI resulted in significantly lower patient-reported QoL. Among type 1 diabetes patients treated with the SGLT2 inhibitor dapagliflozin there were significant (>3-point) improvements in overall patient treatment satisfaction (measured using the Diabetes Treatment Satisfaction Questionnaire).</p>","PeriodicalId":100370,"journal":{"name":"Diabetes, Obesity and Metabolism Now","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/doi2.00009","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity and Metabolism Now","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/doi2.00009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
A research group from Cardiff, UK, has analysed data from the DEPICT clinical trial program and used a novel modelling approach to investigate the inter-relationships between hypoglycaemia, BMI and quality of life (QoL). Episodes of severe hypoglycaemia were associated with a significant increase in the ‘hypoglycemia fear score’ (HFS), and there was evidence that increased HFS and/or increased BMI resulted in significantly lower patient-reported QoL. Among type 1 diabetes patients treated with the SGLT2 inhibitor dapagliflozin there were significant (>3-point) improvements in overall patient treatment satisfaction (measured using the Diabetes Treatment Satisfaction Questionnaire).
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
